Ken Griffin Ventyx Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,765,481 shares of VTYX stock, worth $4.64 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,765,481
Previous 16,200
10798.03%
Holding current value
$4.64 Million
Previous $18,000
20888.89%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VTYX
# of Institutions
122Shares Held
49.4MCall Options Held
70.4KPut Options Held
51.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.9MShares$15.5 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$12.5 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY4.54MShares$11.9 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$8.32 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$8.15 Million0.4% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $149M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...